{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T16:46:01Z","timestamp":1761324361013,"version":"3.41.2"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Sugammadex allows for rapid reversal of muscle relaxation after the use of rocuronium or vecuronium. The lowest recommended dose is 2\u200amg\u200akg<jats:sup>\u22121<\/jats:sup> intravenously when there are two twitches during the train-of-four stimulation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To study the efficacy and risks of a lower dose of sugammadex administered earlier.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN<\/jats:title>\n            <jats:p>Monocentric randomised controlled double-blind study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING<\/jats:title>\n            <jats:p>Academic hospital.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS<\/jats:title>\n            <jats:p>Eighty patients were enrolled and randomised in 8 groups of 10 patients, 56 were finally evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>INTERVENTIONS<\/jats:title>\n            <jats:p>Patients were distributed in two clusters constituting four groups each. In the first cluster, injections were administered after the return of one twitch with the train-of-four (TOF1). In the second cluster, injections were delivered after the return of two twitches with the TOF (TOF2). We created four groups in each cluster for different dosages: placebo, 0.5, 1 or 2\u200amg\u200akg<jats:sup>\u22121<\/jats:sup>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOME MEASURES<\/jats:title>\n            <jats:p>Time between the injection of sugammadex and full recovery (TOF ratio &gt; 0.9) that is expressed in minutes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Fifty-six successive patients were assessed between February and August 2018. The difference to TOF greater than 0.9 was not statistically significant between groups with the same dose administered at different times (<jats:italic toggle=\"yes\">F<\/jats:italic> value = 0.001, <jats:italic toggle=\"yes\">P<\/jats:italic> value = 0.975). There was a significant difference between groups with a different dosage administered at the same time (<jats:italic toggle=\"yes\">F<\/jats:italic> ratio = 28.34; <jats:italic toggle=\"yes\">P<\/jats:italic> value &lt;0.0001). Concerning the time to TOF greater than 0.9 from the time point of TOF1, the timing of the dosages were statistically significant using log rank test (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.0001). No patient presented a reparalysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>No difference between injecting sugammadex at TOF1 or TOF2 was found regarding time to full recovery. Difference regarding sugammadex quantity was found and compatible with other studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>TRIAL REGISTRATION<\/jats:title>\n            <jats:p>clinicaltrials.gov: \u2018BRIDION_ERASME\u2019, EudraCT: 2017-005074-19.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/eja.0000000000001502","type":"journal-article","created":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T18:02:24Z","timestamp":1617559344000},"page":"865-871","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Earlier and lower dose administration of sugammadex"],"prefix":"10.1097","volume":"38","author":[{"given":"Olivier","family":"Duranteau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turgay","family":"Tuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgard","family":"Engelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Van Obbergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ionut","family":"Tabolcea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"R1-20250801","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1213\/00000539-196809000-00007","article-title":"The history of the introduction of curare into medicine","volume":"47","author":"Bennett","year":"1968","journal-title":"Anesth Analg"},{"key":"R2-20250801","first-page":"125","article-title":"Guidelines on muscle relaxants and reversal in anaesthesia","volume":"39","author":"Plaud","year":"2020","journal-title":"Anaesth Crit Care Pain Med"},{"key":"R3-20250801","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s40140-018-0265-6","article-title":"Sugammadex: appropriate use in the context of budgetary constraints","volume":"8","author":"Cammu","year":"2018","journal-title":"Curr Anesthesiol Rep"},{"key":"R4-20250801","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/anae.13862","article-title":"Sugammadex: economic and practical considerations","volume":"72","author":"Ortais","year":"2017","journal-title":"Anaesthesia"},{"key":"R5-20250801","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/00000542-200604000-00009","article-title":"Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study","volume":"104","author":"Sorgenfrei","year":"2006","journal-title":"Anesthes"},{"key":"R6-20250801","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/ALN.0b013e318190bc32","article-title":"Pharmacokinetic-pharmacodynamic model for the reversal of meeting abstracts by sugammadex","volume":"110","author":"Ploeger","year":"2009","journal-title":"Anesthesiology"},{"key":"R7-20250801","first-page":"1","article-title":"Residual neuromuscular blockade and postoperative pulmonary complications: what does the recent evidence demonstrate?","author":"Cammu","year":"2020","journal-title":"Curr Anesthesiol Rep"},{"key":"R8-20250801","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/bja\/aev104","article-title":"Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study","volume":"115","author":"Brueckmann","year":"2015","journal-title":"Br J Anaesth"},{"key":"R9-20250801","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/bja\/aep340","article-title":"Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study\u2020","volume":"104","author":"Staals","year":"2010","journal-title":"Br J Anaesth"},{"key":"R10-20250801","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.annfar.2012.09.006","article-title":"Utilisation du sugammadex chez l\u2019insuffisant r\u00e9nal chronique terminal, dialys\u00e9","volume":"31","author":"Binhas","year":"2012","journal-title":"Ann Fran\u00e7aises d\u2019Anesth\u00e9s R\u00e9anim"},{"key":"R11-20250801","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bjan.2017.10.010","article-title":"Sugammadex by ideal body weight versus 20% and 40% corrected weight in bariatric surgery - double-blind randomized clinical trial","volume":"68","author":"Duarte","year":"2018","journal-title":"Rev Bras Anestesiol"},{"key":"R12-20250801","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/anae.13473","article-title":"Dose of sugammadex in morbidly obese patients","volume":"71","author":"Carron","year":"2016","journal-title":"Anaesthesia"},{"key":"R13-20250801","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s00540-020-02824-5","article-title":"Individual pharmacometric analysis for sugammadex reversal and re-administration of neuromuscular blockade","volume":"34","author":"Kashima","year":"2020","journal-title":"J Anesth"},{"key":"R14-20250801","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.jaip.2020.04.049","article-title":"Does sugammadex have multiple mechanisms for causing anaphylaxis?","volume":"8","author":"Orihara","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R16-20250801","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bja.2019.10.016","article-title":"Comparison of incidence of anaphylaxis between sugammadex and neostigmine: a retrospective multicentre observational study","volume":"124","author":"Orihara","year":"2020","journal-title":"Br J Anaesth"},{"key":"R17-20250801","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12871-016-0281-3","article-title":"A discrete event simulation model of clinical and operating room efficiency outcomes of sugammadex versus neostigmine for neuromuscular block reversal in Canada","volume":"16","author":"Insinga","year":"2016","journal-title":"BMC Anesthesiol"},{"key":"R18-20250801","doi-asserted-by":"crossref","first-page":"110027","DOI":"10.1016\/j.jclinane.2020.110027","article-title":"Sugammadex versus neostigmine for routine reversal of rocuronium block in adult patients: a cost analysis","volume":"67","author":"Hurford","year":"2020","journal-title":"J Clin Anesth"}],"container-title":["European Journal of Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/EJA.0000000000001502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T16:06:08Z","timestamp":1754064368000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/EJA.0000000000001502"}},"subtitle":["A randomised placebo-controlled trial"],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/eja.0000000000001502","relation":{},"ISSN":["0265-0215","1365-2346"],"issn-type":[{"type":"print","value":"0265-0215"},{"type":"electronic","value":"1365-2346"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}